Health · 24 views
Eplontersen trial fails to meet primary endpoint in transthyretin-mediated amyloid cardiomyopathy
The CARDIO-TTRansform trial investigating eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy did not meet its primary efficacy endpoint, according to results presented in a Hot Line session at ESC Congress 2026.
AI Summary
The CARDIO‑TTRansform trial of eplontersen in patients with transthyretin‑mediated amyloid cardiomyopathy failed to achieve its primary efficacy endpoint, as reported during a Hot Line session at the ESC Congress 2026.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Patient-centered financial navigation assistance helps reduce financial toxicity among cancer patientsContinue reading
- Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar rangeContinue reading
- Wearing headphones during surgery may reduce nausea and vomiting afterwardContinue reading
- Adult ADHD; Encouraging Advance Care Planning; Hospital Closures in the U.S.Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow